# MiR-641 targets TMEFF2/MEK/PI3K to promote stem cell characteristics of pancreatic cancer cells

**Authors:** Hongchao Han, Aikun Wang

PMC · DOI: 10.1007/s12672-026-04584-2 · 2026-02-07

## TL;DR

This study shows that miR-641 promotes pancreatic cancer growth and stem cell traits by targeting TMEFF2/MEK/PI3K pathways.

## Contribution

The study identifies miR-641 as a novel oncogenic driver in pancreatic cancer by linking it to stem cell characteristics via TMEFF2/MEK/PI3K regulation.

## Key findings

- MiR-641 is overexpressed in pancreatic cancer tissues and correlates with poor patient survival.
- Knockdown of miR-641 reduces cancer cell proliferation, invasion, and stem-cell-like features in vitro and in vivo.
- MiR-641 promotes stem cell traits by targeting the TMEFF2/MEK/PI3K signaling pathway.

## Abstract

Pancreatic cancer is a common malignant tumor. We focused on exploring the function of miR-641 in stem cell characteristics for pancreatic cancer cells.

MiR-641 expression was analyzed based on The Cancer Genome Atlas (TCGA) pancreatic cancer database and clinical samples. The miR-641 knockdown within pancreatic cancer was performed by cell transfection. CCK8, transwell, and flow cytometry were performed for analyzing cell growth, invasion as well as stem-cell-like features separately. Meanwhile, this study carried out the dual luciferase reporter gene assay. In vivo xenograft tumor assay was also performed.

MiR-641 expression increased in clinical pancreatic cancer tissues and cells compared with normal cells. MiR-641 predicted poor survival rate of pancreatic cancer patients. MiR-641 down-regulation inhibited pancreatic cancer cell proliferation, clone forming ability, invasion and migration. Down-regulation of miR-641 inhibited the capability of sphere-forming, reduced CD133 + and CD44 + cell quantities, and suppressed CD133, CD44, and Oct4 expression in Down-regulation of miR-641 cells. MiR-641 targeted TMEFF2/MEK/PI3K for promoting pancreatic cancer cells’ stem-cell-like characteristics. MiR-641 also promoted tumor growth in vivo.

MiR-641 acts as an oncogene that promotes pancreatic cancer cell growth, invasion as well as stem-cell-like features, which is realized by regulating the expression of TMEFF2.

The online version contains supplementary material available at 10.1007/s12672-026-04584-2.

## Linked entities

- **Genes:** MIR641 (microRNA 641) [NCBI Gene 693226], TMEFF2 (transmembrane protein with EGF like and two follistatin like domains 2) [NCBI Gene 23671], MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], PROM1 (prominin 1) [NCBI Gene 8842], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960], POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460]
- **Diseases:** pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR641 (microRNA 641) [NCBI Gene 693226] {aka MIRN641, hsa-mir-641, mir-641}, TMEFF2 (transmembrane protein with EGF like and two follistatin like domains 2) [NCBI Gene 23671] {aka CT120.2, HPP1, TENB2, TPEF, TR, TR-2}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}
- **Diseases:** pancreatic cancer (MESH:D010190)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12976288/full.md

---
Source: https://tomesphere.com/paper/PMC12976288